Precision BioSciences, Inc. Common Stock
DTILStock
$8.32+97.98%52W
Market Cap$215.19M
P/E19.04x
Div yield—
Beta1.27
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)92.60%
Price vs S&P 500 (4W)39.02%
VGM Score62.88
Market Capitalization$215.19M
P/E Ratio (Annual)19.04x
Earnings Surprise History
Q1 26-0.75est. -0.67
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.30
4.30
4.30
4.30
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DTILPrecision BioSciences, Inc. Common Stock | C | B | B | $8.32 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Precision BioSciences develops genome editing therapeutics based on its proprietary ARCUS platform. The platform's compact size enables efficient delivery to a wider range of cells and tissues using both viral and non-viral methods, potentially providing competitive advantages. The company applies ARCUS to create product candidates for human disease treatment and agricultural applications.